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Chronic inhibition of nitric oxide synthase by Nx-nitro-
L-arginine methyl ester (L-NAME) causes progressive renal
injury with systemic hypertension and interstitial
macrophage infiltration. We have previously shown that
there is local activation of the renin–angiotensin–aldosterone
system in the renal cortex as a major pathogenic feature of
macrophage infiltration. In this study, we measured the
effects of the aldosterone antagonist, spironolactone, on
renal injury in L-NAME-treated male Wistar rats. After 12
weeks of L-NAME-treatment, rats had increased systolic blood
pressure, urinary protein excretion, and serum creatinine and
histological analysis showed glomerulosclerosis, interstitial
fibrosis, and macrophage infiltration. Treatment with
spironolactone significantly prevented these renal changes,
whereas treatment with hydralazine had no effect. The
cortical expression of osteopontin was significantly elevated
in L-NAME-treated rats, and expression of its mRNA
significantly correlated with the number of infiltrating
macrophages and degree of interstitial fibrosis.
Spironolactone treatment markedly suppressed osteopontin
expression. Our results suggest that reduced nitric oxide
bioavailability caused renal inflammation and fibrosis
through an aldosterone receptor–dependent mechanism
associated with osteopontin expression independent of its
systemic hemodynamic effects.
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Angiotensin II (Ang II) is a major player in the progression of
many types of renal diseases.1 Angiotensin-converting
enzyme inhibitor (ACEi) and Ang II type 1 (AT1) receptor
antagonist are clinically effective in reducing proteinuria and
in slowing the progression of proteinuric renal disease,2 and
are regarded as first-choice therapy for patients with chronic
kidney disease. Recent experimental evidence implicated both
aldosterone and Ang II in chronic kidney disease in various
animal models of renal injury.3–8 ACEi and AT1 receptor
antagonist can also mitigate aldosterone levels, although the
suppression is usually not complete.9 Bianchi et al.10
demonstrated that aldosterone antagonist, spironolactone
(Spi), reduced proteinuria and retarded the progression of
chronic kidney disease in patients already treated with ACEi
and/or AT1 receptor antagonist. However, the mechanism
underlying this beneficial effect of aldosterone blockade
remains unclear.
No-nitro-L-arginine methyl ester (L-NAME) is an inhibi-
tor of nitric oxide synthase (NOS), which is known to induce
systemic hypertension in association with progressive renal
tissue injury.11–14 Rats treated with L-NAME are an
established model of progressive chronic kidney disease with
systemic hypertension. These animals exhibit massive
infiltration of macrophages in renal cortex interstitium.14
There is increasing evidence that tubulointerstitial inflam-
mation, especially macrophage infiltration, leads to inter-
stitial fibrosis.15 Previous studies from our laboratory in
L-NAME-treated rats demonstrated local activation of the
renin–angiotensin–aldosterone system in the renal cortex as a
major pathogenic feature of macrophage infiltration. Treat-
ment with ACEi or AT1 receptor antagonist suppressed
macrophage infiltration and conferred renoprotection.16,17
Ang II is a major mediator of inflammation in this model.
Several recent studies also demonstrated that aldosterone
promotes inflammation in kidney disease.3,18
Osteopontin (OPN) is a potent chemotactic and adhesive
factor for macrophages.19,20 Upregulation of OPN expression
in renal tubules is strongly associated with macrophage
infiltration subsequent to tubulointerstitial injury both in
experimental models21 and in patients with kidney disease.22
Furthermore, Blasi et al.3 demonstrated a role for OPN in the
renal inflammatory response following aldosterone/salt
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treatment via macrophage recruitment, whereas the selective
aldosterone blocker, eplerenone, suppressed both OPN
expression and inflammatory changes.
We hypothesized that reduced NO bioactivity induces
renal inflammation and renal fibrosis through an aldosterone
receptor-dependent mechanism, especially in association
with OPN expression. To test this hypothesis, we examined
the effects of aldosterone antagonist Spi in the L-NAME-
treated rat model.
RESULTS
Clinical parameters
Figure 1 shows serial changes in blood pressure and
proteinuria in the four rat groups. Systolic blood pressure
(SBP) did not increase in control rats over the 12-week
study (final measurement 146.0±3.7 mm Hg, mean±s.e.m.).
L-NAME treatment induced a progressive increase in SBP
over time, resulting in severe hypertension (final measure-
ment 239.5±2.2 mm Hg). Rats treated with L-NAMEþ Spi
and L-NAMEþ hydralazine (Hyd) also showed an increase in
SBP. However, these increases were not as high as in the
L-NAME-treated rats and did not change throughout the
study period (final measurement 196.1±4.8 and
211.1±3.8 mm Hg, respectively). Twelve weeks after initia-
tion of treatment, urinary protein was markedly elevated in
the L-NAME (162.6±30.1 mg per 24 h) and L-NAMEþHyd
(219.6±46.5 mg per 24 h) groups, compared with L-NAME-
Spi-treated (43.8±16.8 mg per 24 h) and control
(9.0±1.0 mg per 24 h) rats.
Table 1 lists the other physiological and biochemical
changes induced in each group. Body weight after 12 weeks
was significantly lower in L-NAME and L-NAMEþHyd
groups compared with control rats. Serum creatinine after 12
weeks was higher in both L-NAME and L-NAMEþHyd
groups compared with other groups. Spi treatment did not
induce a significant rise in serum potassium level compared
with the control. Finally, plasma Ang II and aldosterone
levels were significantly higher in rats treated with L-NAME
compared with the control (231.6±42.6 versus 47.1±4.3 pg/
ml, Po0.05, 6562.9±1612.5 versus 129.3±8.9 pg/ml,
Po0.05). Spironolactone prevented the elevation of plasma
Ang II and aldosterone levels.
Effects of Spi on glomerulosclerosis and interstitial fibrosis
Figures 2 and 3 show the typical glomerular and interstitial
pathology in the four experimental groups at the end of the
study period. Control rats were histologically normal
(Figures 2a and 3a). L-NAME-treated rats showed glomerular
damage characterized by arteriolar hyaline change and global
or segmental sclerosis (Figure 2b). L-NAME-treated rats also
showed renal tubular atrophy of the interstitium, as well as
inflammatory cell infiltration and interstitial fibrosis (Figure
3b). Semiquantitative analysis revealed significantly severe
glomerulosclerosis in the L-NAME group compared with
control rats (1.6±0.2 versus 0.3±0.1, Po0.05; Figure 2e),
and this was prevented by Spi treatment (0.5±0.1 versus
1.6±0.2, Po0.05; Figure 2e). Interstitial fibrosis was
prominent in the cortical regions of L-NAME-treated rats
compared with control rats (9.9±0.5 versus 3.2±0.3%,
Po0.05; Figure 3e), and this fibrotic change was also
attenuated in the L-NAMEþ Spi group (3.7±0.3 versus
9.9±0.5%, Po0.05; Figure 3e). In the L-NAMEþHyd
group, the glomerulosclerosis and interstitial fibrosis were
not ameliorated despite the antihypertensive effect (Figures
2e and 3e).
Effects of Spi on OPN mRNA and protein expression
The expression of OPN mRNA in renal cortex was
significantly higher in the L-NAME group than in controls,
and this upregulation was suppressed by Spi treatment
(Figure 4a). Immunohistochemical analysis showed localiza-
tion of OPN protein expression to medullary tubular cells in
control rats, whereas most cortical structures were OPN-
negative (Figure 4b). OPN protein expression was markedly
elevated in L-NAME-treated rats, localizing to the cytoplasm
of tubular epithelial cells (Figure 4c). Strong OPN expression
was noted in areas with severe tissue damage such as atrophic
tubules, although some OPN immunoreactivity was also
observed in mildly injured tubules. This upregulation of
OPN protein expression was markedly suppressed in the L-
NAMEþ Spi group (Figure 4d).
Effects of Spi on macrophage infiltration
Macrophages, detected by immunohistochemical staining
for ED-1, were rarely observed within the tubular inter-
stitium of control rats (Figure 5a), whereas L-NAME
rats showed significant macrophage infiltration (Figures 5b
and e, 20.3±2.3 cells per field in L-NAME group versus
0.4±0.1 cells per field in controls, Po0.05). Macrophage
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Figure 1 | Changes in blood pressure and proteinuria. (a)
Systolic blood pressure measured by the tail-cuff method and (b)
proteinuria. Values are mean±s.e.m. (J) Control, (K) L-NAME-
treated, (&) L-NAMEþ Spi-treated, and (’) L-NAMEþHyd-
treated. *Po0.05 versus control rats, zPo0.05 versus L-NAME-
treated rats, wPo0.05 versus L-NAMEþ Spi-treated rats.
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infiltration was markedly suppressed by Spi treatment
(Figure 5c and e, 20.3±2.3 versus 1.1±0.5 cells per field,
Po0.05).
Correlation between OPN expression and number of
ED-1-positive cells and interstitial fibrosis
We next analyzed the correlation between OPN mRNA
expression and macrophage infiltration and interstitial
fibrosis in the model rats (Figure 6). The degree of OPN
mRNA expression correlated well with both the number
of ED-1-positive cells (r¼ 0.725 and Po0.05) and the
level of interstitial fibrosis (r¼ 0.753 and Po0.05) in all
groups.
Effects of Spi on transforming growth factor-b1 and a-smooth
muscle actin protein expression
Figure 7 shows representative immunostaining for trans-
forming growth factor (TGF)-b1 (Figure 7a–d) and a-smooth
muscle actin (a-SMA) (Figure 7e–h) in kidney sections from
all groups. Positive immunostaining for TGF-b1 and a-SMA
was detected only occasionally in the control rats (Figure 7a
and e). L-NAME-treated rats showed immunoreactivity for
TGF-b1 in the cytoplasm of tubular epithelial cells (Figure
7b) and a-SMA expression in interstitial areas (Figure 7f). Spi
treatment suppressed TGF-b1 and a-SMA expression (Figure
7c and g).
DISCUSSION
This study on L-NAME–induced renal damage demonstrated
that aldosterone blockade by Spi suppresses urinary protein
excretion and inhibits both glomerulosclerosis and fibrosis
associated with attenuation of the renal inflammatory
process. The results indicated that aldosterone contributes
to renal inflammation in this rat model of chronic kidney
disease with systemic hypertension.
Table 1 | Clinical parameters of the four experimental groups
Control L-NAME L-NAME+Spironolactone L-NAME+Hydralazine
Body weight (g)
Before 368±3 363±3 362±5 364±3
4 week 473±11 453±8 450±9 456±8
8 week 538±12 501±11* 516±5 505±10
12 week 577±11 501±20* 534±17 491±18*
Serum creatinine (mg/100 ml)
12 week (mEq/l) 0.26±0.02 0.77±0.15* 0.36±0.02z 0.74±0.14*w
Serum potassium (pg/ml)
12 week 4.6±0.2 5.2±0.3 4.9±0.2 4.9±0.3
Plasma aldosterone (pg/ml)
12 week 129.3±8.9 6562.9±1612.5* 1447.3±536.6z 4570.6±1403.3*
Plasma angiotensin II (pg/ml)
12 week 47.1±4.3 231.6±42.6* 56.1±11.3z 141.9±48.0
L-NAME, No-nitro-L-arginine methyl ester.
Data are expressed as mean±s.e.m.
*Po0.05 versus control rats, zPo0.05 versus L-NAME treated rats, wPo0.05 versus L-NAME/spironolactone treated rats.
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Figure 2 | Representative photomicrographs of renal tissue and
semiquantitative analysis of glomerulosclerosis indices. Periodic-
acid Schiff staining of sections from (a) control rats, (b) L-NAME-
treated rats after 12 weeks, (c) L-NAMEþ Spi-treated rats after 12
weeks, (d) L-NAMEþHyd-treated rats after 12 weeks, and (e)
glomerulosclerosis in each group; original magnification  200.
Values are mean±s.e.m. *Po0.05 versus control rats, zPo0.05 versus
L-NAME-treated rats, wPo0.05 versus L-NAMEþ Spi-treated rats.
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Similar to previous reports,16,17 L-NAME-treated rats in
this study developed significant hypertension, proteinuria,
severe renal inflammation marked by a large number of
infiltrating macrophages, and renal fibrosis. Prolonged NOS
inhibition by L-NAME activates both systemic and local renal
Ang II, regarded as a major mechanism of renal injury in this
animal model.11,12,16,23,24 Our previous study demonstrated
that ACEi and AT1 receptor antagonist confer pathophysio-
logical renoprotection in L-NAME-treated rats.16,17 However,
Ang II also stimulates the synthesis of aldosterone. Further-
more, Klar et al.25 demonstrated that aldosterone exerts a
direct positive effect on renin gene expression in renal
juxtaglomerular cells. It has been demonstrated also that
aldosterone upregulates angiotensin-converting enzyme
mRNA expression and its enzymatic activity in rat endo-
thelial cells.26 These effects are blocked by Spi. In addition,
previous experiments demonstrated that chronic NO block-
ade by L-NAME induces adrenal aldosterone synthesis.27,28 In
the present study, plasma Ang II and plasma aldosterone
concentrations were increased in L-NAME-treated rats. The
results showed that inhibition of aldosterone by Spi also
attenuated proteinuria and renal inflammation in L-NAME-
treated rats. Spi might inhibit the positive feedback by
suppressing the effects of aldosterone as well as the elevated
concentrations of plasma Ang II and aldosterone in L-NAME-
treated rats.
In addition to renal protection, Spi induced a significant
decrease in blood pressure, thereby possibly augmenting the
attenuation of renal damage and inflammation. However,
reducing the hypertension using Hyd had a much smaller effect
on the prevention of renal damage than Spi treatment. Of note,
there was no significant difference in SBP between L-NAME-
Spi and L-NAMEþHyd groups. These findings suggest that
aldosterone participates in the L-NAME–induced renal damage
independently of systemic hemodynamic effects.
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Figure 3 | Representative photomicrographs of renal tissue
and semiquantitative analysis of interstitial fibrosis. Masson
trichrome staining of sections from (a) control rats, (b) L-NAME-
treated rats after 12 weeks, (c) L-NAMEþ Spi-treated rats after 12
weeks, (d) L-NAMEþHyd-treated rats after 12 weeks, and (e)
percentage of interstitial fibrosis in each group; original
magnification  200. Values are mean±s.e.m. *Po0.05 versus
control rats, zPo0.05 versus L-NAME-treated rats, wPo0.05 versus
L-NAMEþ Spi-treated rats.
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Figure 4 | Renal expression of OPN mRNA and
immunohistochemistry for OPN protein. (a) Renal cortical OPN
mRNA was measured by real-time RT-PCR. Immunohistochemistry
of OPN protein in (b) control rats, (c) L-NAME-treated rats after 12
weeks, (d) L-NAMEþ Spi-treated rats after 12 weeks, and (e)
L-NAMEþHyd-treated rats after 12 weeks. Positive staining for
OPN was observed mainly in the flattened epithelial cells of the
dilated tubular lumen and in cell debris for L-NAME- and
L-NAMEþHyd-treated rats. Values are mean±s.e.m. *Po0.05
versus control rats, zPo0.05 versus L-NAME-treated rats, wPo0.05
versus L-NAMEþ Spi-treated rats; original magnification  200.
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Previous studies, in vivo27,28 and in vitro,29–32 indicated
that endogenous NO directly reduces adrenal aldosterone
synthesis and that NO inhibition induces adrenal aldosterone
synthesis. Nithipatikom et al.31 demonstrated that long-term
administration of NO inhibits aldosterone synthesis in zona
glomerulosa cells by downregulation of the expression of AT1
receptors. Usui et al.27 demonstrated that inhibition of NO
synthesis by L-NAME increases AT1 receptor expression and
induces adrenal aldosterone synthesis. Moreover, Tsukamoto
et al.28 demonstrated that chronic inhibition of NO synthesis
increases the expression of CYP11B2 mRNA in adrenal
glands of rats and induces adrenal aldosterone synthesis. On
the other hand, aldosterone might suppress NOS activity in
L-NAME-treated rats. Pechanova et al.33 demonstrated that
Spi increased endothelial NOS protein expression and
prevented the depression of NOS activity in L-NAME-treated
rats. Thus, in addition to the direct effect of aldosterone
blockade, Spi might prevent a vicious cycle between
activation of renin–angiotensin–aldosterone system and
reduced NO bioavailability in the L-NAME-treated rat model.
In some experimental models of kidney disease related to
aldosterone, such as aldosterone/salt-treated rats model,3 a
salt load was needed to induce renal injury. Salt loading is
reported to enhance reactive oxygen species generation.
Kitiyakara et al.34 demonstrated that high salt intake induces
oxidative stress, which is associated with activated renal-
reduced nicotinamideadenine dinucleotide phosphate oxi-
dase, and decreases intracellular superoxide dismutase. In our
experiments, all animals were fed normal-salt diet (0.45%
Na) during the study. We thought that L-NAME, in addition
to activation of renin–angiotensin–aldosterone system, de-
creased NO level and increased oxidative stress and induced
renal injury without salt.
The L-NAME-treated rat model is characterized by
massive interstitial infiltration of macrophages.14,17 Our
previous study associated this macrophage infiltration with
Ang II.17 Considerable recent evidence also indicates that
aldosterone induces vascular inflammation via activation of
proinflammatory cytokines,35,36 and some studies suggested
that such activation in the kidney leads to renal inflamma-
tion.3,18 The present study confirmed that blocking aldoster-
one using Spi reduces macrophage infiltration.
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Figure 5 | Representative images of immunohistochemistry
for ED-1 and quantification of ED-1-positive cells within the
tubular interstitium. (a) Control rats, (b) L-NAME-treated rats,
(c) L-NAMEþ Spi-treated rats, (d) L-NAMEþHyd-treated rats, and
(e) ED-1-positive cell number in each group. L-NAME-treated rats
showed focal accumulation of ED-1-positive cells within the
tubular interstitium compared with control rats, especially in
injured areas. Spi significantly suppressed the number of
ED-1-positive cells. Values are mean±s.e.m. *Po0.05 versus
control rats, zPo0.05 versus L-NAME-treated rats, wPo0.05 versus
L-NAMEþ Spi-treated rats; original magnification  200.
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Figure 6 | Correlation of OPN mRNA expression with
macrophage accumulation and tubulointerstitial injury. OPN
mRNA expression correlated significantly with the number of (a)
ED-1-positive cells and (b) interstitial fibrosis. Data were analyzed
by Pearson’s single correlation coefficient; in a, r¼ 0.725 and
Po0.05 and in b, r¼ 0.753 and Po0.05.
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There is considerable experimental evidence that OPN is
closely related to macrophage infiltration. OPN is expressed
in some renal distal tubules in normal rat kidneys. In several
models of glomerular and tubulointerstitial injury, tubular
OPN expression is markedly increased.37,38 Overexpression of
OPN in the tubules correlated with the degree and site of
interstitial macrophage infiltration and development of
interstitial fibrosis.37,38 This was confirmed in OPN-gene
knockout mice,39 and in animals treated with antisense
probes or anti-OPN antibody,40 where significant reduction
in macrophage infiltration and renal fibrosis was demon-
strated. The present study showed upregulation of OPN at
both the mRNA and protein levels in L-NAME-treated rats in
parallel with increased macrophage numbers, as indicated by
ED-1-positive cells. This OPN upregulation was suppressed
significantly by Spi, concomitant with a decrease in
macrophages. The present study thus implicates aldosterone
in the upregulation of OPN in the L-NAME rat model, and
demonstrates a renoprotective role for Spi via the down-
regulation of OPN. The mechanism by which aldosterone
stimulates OPN expression in this model is not fully
understood. Although aldosterone could act indirectly, some
studies showed that treatment with aldosterone induced
OPN expression directly, both in vivo3 and in vitro.41
Recently, Irita et al.41 demonstrated that aldosterone induced
mineralocorticoid receptor-mediated OPN expression
through activation of nuclear factor-kB and suggested that
aldosterone is important in renal fibrosis through the
induction of OPN in renal fibroblasts. Nuclear factor-kB
activation has been already demonstrated in L-NAME-treated
rats.42 We suspect that OPN is upregulated by aldosterone
through activation of nuclear factor-kB in the L-NAME-
treated rat model. Our results demonstrated that the
aldosterone antagonist Spi inhibited OPN mRNA upregula-
tion and reduced renal inflammation. These findings suggest
that aldosterone could induce renal inflammation through a
mineralocorticoid receptor-dependent mechanism.
Aldosterone could cause renal injury in L-NAME-treated
rats by pathways other than inflammation. Aldosterone
injection in normal rats provoked renal TGF-b1 synthesis,43
and TGF-b1 is a major fibrogenic cytokine in both interstitial
fibrosis and glomerulosclerosis.44 Many experiments also
suggested that fibroblasts, particularly myofibroblasts, dis-
tinguished by a-SMA expression, are key cells in the
development of renal interstitial fibrosis.45,46 In this
study, we observed many TGF-b1- and a-SMA-positive cells
in L-NAME-treated rats. Spi treatment reduced the
expression of both proteins. TGF-b1 is also a key
mediator of tubular epithelial cell transdifferentiation into
a-SMA-positive myofibroblasts.47 In addition, Zhang et al.48
recently demonstrated that aldosterone induces epithelial–-
mesenchymal transition in renal epithelial tubular cells.
Aldosterone might therefore cause renal injury in the
L-NAME rat model, in part, through myofibroblast trans
differentiation.
In conclusion, our study demonstrated that reduced NO
bioactivity induces renal inflammation and renal fibrosis
through an aldosterone receptor-dependent mechanism.
These inflammatory and fibrotic effects may result from
upregulation of OPN independent of systemic hemodynamic
effects.
MATERIALS AND METHODS
Animals
Experiments were conducted on 10-week-old male Wistar rats,
weighing 320–350 g. Rats were treated according to protocols
approved by the Kyushu University Animal Care Committees at
the Center Animal Care facility. These experiments were reviewed
and approved by the Committee on Ethics of Animal Experiments,
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Figure 7 | Representative images of immunohistochemistry
for TGF-b1 (a–d) and a-SMA (e–g) in renal cortex. (a, e) Control
rats, (b, f) L-NAME-treated rats, (c, g) L-NAMEþ Spi-treated rats,
and (d, h) L-NAMEþHyd-treated rats. TGF-b1 and a-SMA protein
was virtually absent from the cortical tubules and interstitium of
control rats, but was strongly expressed in the cortex of L-NAME-
treated rats. Spi treatment reversed the increase in TGF-b1 and
a-SMA expression; original magnification  100.
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Kyushu University Faculty of Medicine, and were conducted
according to the Guidelines for Animal Experiments of the
Kyushu University Faculty of Medicine. The animals were housed
in a temperature-controlled room with a 12-h light–dark cycle.
Animals were allowed 1 week to adjust after arrival and allowed
free access to food and water during the entire study. All animals
were fed normal-salt diet (0.45% Na; CLEA Japan, Tokyo,
Japan) throughout the study. Rats were killed by intraperitoneal
injection of 50 mg/kg sodium pentobarbital (Dinabot Co., Osaka,
Japan).
Experimental design
The rats were separated randomly into four groups and treated for
12 weeks. The control group was given normal drinking water
(n¼ 8). The disease control group received drinking water contain-
ing L-NAME (0.5 mg/ml, n¼ 8; Sigma, St Louis, MO, USA). At this
concentration, the daily intake of L-NAME was 50 mg/kg/day. The
third group received L-NAME in the drinking water and the
aldosterone receptor blocker Spi (100 mg/kg/day, n¼ 8; Sigma),
incorporated into the rodent diet. The fourth group received
L-NAME with Hyd (6 mg/kg/day, n¼ 8; Wako Pure Chemical
Industries, Osaka, Japan) in the drinking water. The actual volumes
of consumed chow and drinking water were measured separately
every 4 weeks while the rats were in metabolic cages (CLEA Japan).
We also confirmed that individual values for food and water intake
were similar among the groups. At the end of the study, blood
samples were collected by cannulation of the abdominal aorta, and
stored at 80 1C. The kidneys were perfused with cold phosphate-
buffered saline (pH 7.4) and then excised. Renal capsules from the
left kidney were gently removed and the cortex removed using
scissors. The cortical tissue samples were snap-frozen in liquid
nitrogen and stored at 80 1C for molecular analysis. Tissue from
the right kidney was fixed in 4% paraformaldehyde (Wako Pure
Chemical Industries) for later use.
Clinical parameters
Rat body weight and SBP were measured every 4 weeks during
the study. Blood pressure was monitored in the conscious state using
the tail-cuff method (BP-monitor MK-2000; Muromachi Kikai,
Tokyo, Japan). Twenty-four-hour urine samples were collected
every 4 weeks in metabolic cages during food and water intake
measurement. Urinary protein excretion was measured by the
pyrogallol sulfonphthalein method. Serum creatinine as well as
blood urea nitrogen and potassium were analyzed using a Hitachi
7170 autoanalyzer (Hitachi, Tokyo, Japan). Finally, plasma Ang II
and aldosterone levels were analyzed by radioimmunoassay.
Histochemical staining and quantification
The kidney tissues fixed in 4% paraformaldehyde were embedded in
paraffin for light microscopy. Two-micron sections were stained
with periodic acid-Schiff reagent and Masson trichrome. Glomerulo-
sclerosis was assessed on periodic acid-Schiff stained sections.
Glomerular mesangial matrix was assessed semiquantitatively on
100 glomeruli selected at random, and the degree of expansion
determined using the method of Raij et al.49 The percentage of each
glomerulus occupied by mesangial matrix was estimated and scored
as follows: 0, no lesion; 1þ , 1–25%; 2þ , 26–50%; 3þ , 51–75%; and
4þ , 76–100%. The number of glomeruli showing no lesion was set
to n0; similarly, 1þ to n1, 2þ to n2, 3þ to n3, and 4þ to n4.
The sclerosis index for 100 glomeruli was calculated by the following
formula: glomerulosclerosis index¼ ((0 n0þ 1 n1þ 2 n2þ
3 n3þ 4 n4)/100) 100. Interstitial fibrosis was assessed
on the Masson trichrome-stained sections. A representative section
of whole cortex was analyzed by the point-counting technique
to obtain the relative interstitial volume,50 using a 121-point
(100 square) eyepiece micrometer. Renal interstitial injury was
estimated by counting the relative interstitial volume, using a
minimum of five sections (605 points) randomly selected in all
groups.
Immunohistochemistry and quantification
Kidney sections were immunostained for ED-1, OPN, TGF-b1, and
a-SMA as described previously.51 Briefly, 2-mm-thick sections were
deparaffinized and then treated to inactivate endogenous peroxidase
by incubation in 0.3% H2O2 in methanol for 30 min. The sections
were then preincubated with 5% skim milk to decrease nonspecific
binding and incubated overnight at 4 1C with anti-ED-1 (1:2000;
Chemicon International, Temecula, CA, USA), anti-OPN (1:200;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-TGF-b1
(1:100; Santa Cruz Biotechnology), or anti-a-SMA (1:5; Nichirei,
Tokyo, Japan) antibody. After extensive washing, the sections were
incubated with biotinylated secondary antibodies for 1 h at room
temperature followed by horseradish peroxidase conjugated strepta-
vidin (100 mg/ml; Nichirei) for 30 min. The horseradish peroxidase
was visualized by reaction with 3,30-diaminobenzidine tetrahy-
drochloride (DAB; Nichirei) and H2O2. ED-1-positive cells in the
cortex were counted to quantify infiltrating interstitial macrophages.
The numbers from 20 consecutive high-power fields ( 200) were
averaged (cells per high-power field).
RNA isolation and real-time PCR
Total RNA was isolated from the renal cortical tissue using TRIzol
(Invitrogen Life Technologies, Carlsbad, CA, USA), according to the
protocol provided by the manufacturer. One-step real-time reverse
transcription (RT)-PCR was conducted using the LightCycler
system (Roche Diagnostics, Mannheim, Germany) and 5 ng of total
RNA. The primers and probes for rat OPN and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) were as follows: OPN forward
primer, 50-GGAGTATAAGCAGAGGGCCA-30; OPN reverse primer,
50-CGCCTGACTGTCGATAGCAT-30, GAPDH forward primer, 50-
TGAACGGGAAGCTCACTGG-30; GAPDH reverse primer, 50-
TCCACCACCCTGTTGCTGTA-30. Each RT–PCR reaction was
performed in duplicate wells using a Taq Man One-step cyber
RT–PCR Kit (Takara Biotechnology, Tokyo, Japan). RT reactions
were performed at 42 1C for 15 min and 95 1C for 2 min.
PCR was performed for 40 cycles at 95 1C for 15 s and at
60 1C for 20 s. GAPDH expression was also analyzed by real-time
RT-PCR as a control under the same conditions as for OPN.
The relative expression of OPN mRNA was normalized against
GAPDH.
Statistical analysis
Results are presented as mean±s.e.m. Differences between four
groups were examined for statistical significance using one-way
analysis of variance followed by a modified t-test with Bonferroni
correction using the StatView program (Abacus Concepts, Berkeley,
CA, USA). The Pearson single correlation coefficient was used to
correlate OPN mRNA expression with macrophage infiltration and
tubulointerstitial injury. A P-value less than 0.05 was considered
statistically significant.
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